Abstract

Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [[1, 2]].

Highlights

  • Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [1,2]

  • The AUC10-60 min of mean arterial pressure values (MAP) plot was significantly lower in the control group, and both treatments produced significant increases in

  • Noradrenaline added to the sildenafil infusion was found to generate better values in the cardiovascular parameters (p < 0.01)

Read more

Summary

Introduction

Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [1,2]. Results Verapamil infusion produced decreases in the mean arterial pressure values (MAP).

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call